Lexeo Therapeuticsの空売り状況は、投資家がLexeo Therapeuticsの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Lexeo Therapeutics (NASDAQ:LXEO) 株価情報, 空売り情報

LEXEO THERAPEUTICS INC

Lexeo Therapeutics

Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.

Lexeo Therapeutics Inc

News

Buybacks

ECARX Upsizes Share Repurchase Program By $20M To $40M, Extends Term Through 2026

Macro Economic Events

Economics

Treasury Secretary Bessent Said On VAT Tax With Europe:, Everything Is On The Table

Health Care

General

CMND

Clearmind Medicine Announced The Publication Of An International Patent Application In Collaboration With Yissum Research Development Company Of The Hebrew University Of Jerusalem, The Patent Application Covers Psychedelic-based Compounds For Mental Health Disorders And Addiction

JP Morgan analyst Domingos Falavina upgrades Nu Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NU#NYSE">NU</a>) from Neutral to Overweight and lowers the price target from $14 to $13.

Upgrades

Price Target

Analyst Ratings

JP Morgan Upgrades Nu Holdings to Overweight, Lowers Price Target to $13

Treasury Secretary Bessent, In CNBC Interview, Said: Tariff Negotiations Result Of Massive Inbound Calls, Not Market

TRAK

ReposiTrak Adds 50 New Grocery Suppliers To The Queue Of Companies Joining Rhe ReposiTrak Traceability Network

ReposiTrak Has Added 50 New Grocery Suppliers To The Queue Of Companies Joining The ReposiTrak Traceability Network To Exchange Intricate, FDA-Required Key Data Elements For Each Critical Tracking Event In Their Supply Chains With The Goal Of Meeting Traceability Requirements Before FDA's 2028 Deadline

HC Wainwright &amp; Co. analyst Oren Livnat reiterates Verrica Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRCA#NASDAQ">VRCA</a>) from Neutral to Neutral.

Reiteration

VRCA

HC Wainwright & Co. Reiterates Neutral on Verrica Pharmaceuticalsto Neutral

Hiroshi Nishijima, CEO of Zoomcar, stated, "Zoomcar Vouchers is designed to provide users with freedom of choice and greater flexibility in planning future travel. We're finding greater ways to deepen the relationships with our customers, while encouraging repeat bookings and long-term brand loyalty. Building trust with our users is key to building a sustainable long-term business."

ZCAR

Zoomcar Debuts Vouchers In India, Confirms No Impact From US-India Tariffs

&nbsp;Enanta's Phase 2a Study of EDP-323 Shows Reduced Mucus and Faster Viral Clearance in RSV-Infected Adults

ENTA

Enanta Highlights RSV Polymerase Inhibitor Data At ESCMID 2025 In Vienna

Walmart+ Week To Provide Exclusive Member Benefit Savings

<ul>
<li>The Company had previously announced its intention to explore all strategic options for the Display business and to classify the Display business as discontinued operations when it reports Q1 results in May in order to focus as a pure-play Power discrete and Power IC company and to achieve profitable revenue growth and maximize shareholder value.&nbsp;</li>
<li>However, the Company has not been able to consummate a transaction following several months of discussions with several interested parties on terms that the Company's Board of Directors believed were in the best interests of the Company and its stockholders. Therefore, the Company has already begun notifying its customers impacted by this decision.&nbsp;</li>
</ul>

Magnachip Semiconductor Approved A Plan To Shut Down The Company's Display Business By The End Of The Second Quarter Of 2025

Guidance

TLRY

Tilray Brands Cuts FY25 Revenue Guidance From $950M - $1B To $850M - $900M Vs. $893.060M Est.

UCAR

UCAR Unveils UOTTA Battery Swap Station In Bangkok, Launching First Operational Ecosystem In Southeast Asia With SUSCO

As major indices have moved into the oversold territory, led by the tariff-fueled selloff over the last three sessions, CNBC&#8217;s Jim Cramer has questioned the Tuesday up move in futures.
What Happened: &#8220;What a tough moment,&#8221; said Cramer in an X post, who is the host of CNBC's ‘Mad Money&#8217;.
According to him, the market looks technically ready for a bounce due to being oversold, and futures point to a strong open. However, the lack of clear positive news making the futures surge might make investors cautious about buying into this initial strength.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">What a tough moment. We are so oversold and the futures are so high that buying here is a very difficult chore. We have been there before and the market can be a coiled spring without news
&mdash; Jim Cramer (@jimcramer) <a href="https://twitter.com/jimcramer/status/1909513930080149729?ref_src=twsrc%5Etfw">April 8, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
In the following X post, he also questioned whether buyers were discounting <a href="https://www.benzinga.com/markets/25/04/44677506/china-resolutely-opposes-trumps-50-tariff-threat-vows-countermeasures-as-trade-tensions-jolt-markets?_gl=1kzrvdi_gcl_auNzQyMjgxNjUuMTczNzYwNzI4NQ.._gaZGVsZXRlZA.._ga_V7ZK73W7N0&#x2A;MTc0NDEwMDY0OS4yNDkuMC4xNzQ0MTAwNjQ5LjAuMC4w">China&#8217;s retaliatory tariffs</a> that could worsen the state of the economy. Cramer wonders if the current buying is rational or it &#8220;is all a big trap?&#8221; He&#8217;s cautious about buying into the current positive momentum after successfully avoiding panic selling the day before.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Are the buyers gambling that it doesn&#39;t matter if we put another 50 on China, that stocks are that low? Or is is all a big trap? We succeeded in not selling into yesterday&#39;s panic. But can we really buy into today&#39;s euphoria?
&mdash; Jim Cramer (@jimcramer) <a href="https://twitter.com/jimcramer/status/1909515797115842722?ref_src=twsrc%5Etfw">April 8, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/general/market-summary/25/04/44679853/wall-street-eyes-recovery-as-sp-500-nasdaq-futures-rise-after-trumps-tariff-driven-selloff-wipes-out-9-trillion-in-six-weeks">Wall Street Eyes Recovery As S&amp;P 500, Nasdaq Futures Rise After Trump&#8217;s Tariff-Driven Selloff Wipes Out $9 Trillion In Six Weeks</a>
Why It Matters: The technical analysis of the exchange-traded funds tracking the S&amp;P 500 and the Nasdaq 100 indices, SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), shows that both of them have slipped into the oversold zone.
According to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>, SPY was trading below its short and long-term simple daily moving averages, and its momentum indicator signaled a bearish trend with a negative 14.73 MACD line.
Its relative strength index at 23.11 was below the threshold of 30, indicating that it was in the oversold territory and could be poised for a bounce back.
<figure class="wp-block-image size-large"><a href="https://pro.benzinga.com/dashboard"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08055227/SPY-tech-chart-new-1024x576.png" alt="" class="wp-image-861561" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08055227/SPY-tech-chart-new-1024x576.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08055227/SPY-tech-chart-new-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08055227/SPY-tech-chart-new-768x432.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08055227/SPY-tech-chart-new-1536x864.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08055227/SPY-tech-chart-new.png 1920w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Similarly, QQQ was also below its short and long-term moving averages, having a negative MACD line of 16.90, suggesting a bearish trend. Its RSI at 28.59 was also in the oversold zone.
<figure class="wp-block-image size-large"><a href="https://pro.benzinga.com/dashboard"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08055237/QQQ-tech-chart-new-1024x576.png" alt="" class="wp-image-861566" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08055237/QQQ-tech-chart-new-1024x576.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08055237/QQQ-tech-chart-new-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08055237/QQQ-tech-chart-new-768x432.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08055237/QQQ-tech-chart-new-1536x864.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08055237/QQQ-tech-chart-new.png 1920w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Cramer, in an earlier post, also expressed skepticism about Monday's post-market <a href="https://www.benzinga.com/markets/equities/25/04/44677995/jim-cramer-says-market-rebound-feels-strange-after-nine-nights-of-losses-things-arent-better-as-stock-futures-surge-over-1">futures rebound</a>, calling it "strange" following nine consecutive down days in futures trading.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">We don&#39;t want to se the futures up this much. So strange. We have come in down every night for 9 nights. Now the futures are up huge. Where are the sellers. Things aren&#39;t &quot;better&quot; now unless we are at levels people, at last, like.
&mdash; Jim Cramer (@jimcramer) <a href="https://twitter.com/jimcramer/status/1909410023681204517?ref_src=twsrc%5Etfw">April 8, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Price Action: As of Monday, the S&amp;P 500 was 17.65% below its previous record high of 6,147.43 points. The Nasdaq 100 continued to hover in the bear market territory, 21.56% lower from its previous high of 22,222.61 points. The Dow Jones, on the other hand, was down by 15.77% from its 52-week high of 45,073.63 points.
In premarket on Tuesday, the SPY was up 1.28% to $510.85, while the QQQ advanced 1.06% to $428.17, according to Benzinga Pro data.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44679385/market-enters-risk-off-mode-as-analyst-predicts-this-signal-flashing-warnings-similar-to-2020-and-2008-crisis" target="_blank" rel="noreferrer noopener">Market Enters ‘Risk-Off' Mode As Analyst Predicts This Signal Flashing Warnings Similar To 2020, 2008 Crisis</a></li>
</ul>
Image via Shutterstock

Analyst Color

Equities

Government

Macro Notification

Market Summary

Regulations

Broad U.S. Equity ETFs

Futures

Technicals

Markets

Trading Ideas

ETFs

Jim Cramer Cautions Against Jumping In As Oversold Market Sparks Futures Rebound Without Clear Catalyst: 'Is It All A Big Trap?'

Transaction Expected to Help TRNR Generate More than $65M in 2025 Revenue on a Pro Forma basis
Wattbike is the Leading, Indoor-Bike Brand for Elite-Athlete Training and is Used by Olympians and Professional Sports Teams Worldwide - Including the NFL, NBA, MLB, NHL and Premier League
TRNR Listing, Global Distribution Network to Help Wattbike Accelerate Growth, Especially in Key Markets Like US and Germany; Wattbike's Deep Penetration into Leading UK Gyms and Expanding D2C Customer Base to Similarly Speed Up Step-Changes to TRNR Top and Bottom Lines
Transaction Delivers on Previously-Announced LOI, Combines Highly Complementary Businesses to Create a Scaled, International Operation Anchored in the US, Germany and UK, the #1, <a href="https://interactivestrength.com/germany-spotlight/">#2</a> and <a href="https://interactivestrength.com/uk-market-distribution/">#3 Fitness Markets</a> Globally
Deal - Expected to be TRNR's 3rd Within a Year-and-a-Half - Builds on its Transformative Portfolio Strategy for Creating Long-Term Shareholder Value
Acquisition Expected to Close as Early as the Second Quarter of 2025, Subject to Standard Regulatory Requirements
 &nbsp;

New ETFs

TRNR

Interactive Strength Expands Global Footprint With Wattbike Acquisition, Targeting Over $65M In 2025 Pro Forma Revenue

<ul>
<li>After a single course of therapy, Descartes-08-treated participants were observed to sustain deep responses through long-term follow-up, with an average 4.8-point reduction in MG-ADL at Month 12</li>
<li>Deepest and most compelling sustained responses observed in Descartes-08-treated participants who did not have prior exposure to biologic therapies, with an average 7.1-point reduction in MG-ADL and 57% of patients in this subgroup maintaining minimum symptom expression at Month 12</li>
<li>Safety profile consistent with previously reported data and continues to support outpatient administration</li>
<li>Phase 3 AURORA trial on track to dose first patient in 2Q25</li>
</ul>

Biotech

RNAC

Cartesian Therapeutics Announced 12-month Efficacy And Safety Data From Phase 2b Trial Of Descartes-08 In Participants With Generalized Myasthenia Gravis. Participants Dosed With A Single Six-week Course Of Treatment Of Descartes-08 Were Observed To Continue To Experience A Sustained Benefit In Symptoms

Jefferies analyst David Windley upgrades Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) from Underperform to Hold and raises the price target from $53 to $64.

Jefferies Upgrades Centene to Hold, Raises Price Target to $64

HC Wainwright &amp; Co. analyst Yi Chen initiates coverage on VolitionRX (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VNRX#AMEX">VNRX</a>) with a Buy rating and announces Price Target of $2.5.

Initiation

VNRX

HC Wainwright & Co. Initiates Coverage On VolitionRX with Buy Rating, Announces Price Target of $2.5

HUM: 16% &#x7C; <a href="https://www.benzinga.com//node/44674240">Shares of health insurers are trading higher following a WSJ report indicating the Trump administration will increase payment rates for Medicare insurers.</a>
&nbsp;
MRVL: 7% &#x7C; <a href="https://www.benzinga.com//node/44680589">Marvell Technology shares are trading higher after Infineon Technologies agreed to acquire its Automotive Ethernet Business for $2.5 billion in cash.</a>
&nbsp;
NYXH: 62% &#x7C; <a href="https://www.benzinga.com//node/44678177">Nyxoah Nears FDA Approval For Genio System Following Approvable Letter Confirming PMA Requirements Are Substantially Met</a>

Movers

MRVL

NYXH

Market-Moving News for April 8th

Earnings

Press Releases

Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights

Lexeo Therapeutics to Participate in Upcoming Investor Conferences

Lexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Conference

Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer's Disease, at the Clinical Trials on Alzheimer's Disease (CTAD) Conference

Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results

Satellos to Participate in Duchenne KOL Investor Webinar on December 4, 2024

Management

Lexeo Therapeutics Appoints Kyle Rasbach as Chief Financial Officer

Lexeo Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Lexeo Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational Study

Comments

Lexeo Therapeutics

空売り

Lexeo Therapeutics (NASDAQ:LXEO) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル